Back to Stakeholders

Specialized Academic Departments and Institutes Independent Academic Research Groups

Icahn School of Medicine at Mount Sinai

United States

13 Trials

Icahn School of Medicine at Mount Sinai is a leading US academic medical institution home to the Parsons Research Center for Psychedelic Healing, which runs rigorous clinical trials of MDMA- and psilocybin-assisted therapies for PTSD and trauma in veteran and civilian populations.

Quick Facts

Type: Other
HQ: United States
Website: Visit

Sponsored Trials

9

Psilocybin Mechanism of Action (MOA)

Start Date: February 1, 2025
Compounds: Psilocybin, Placebo

Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression (KAP)

Start Date: January 1, 2025
Compounds: Ketamine

Neural Circuit Effects of Ketamine in Depression

Start Date: January 31, 2024
Compounds: Ketamine, Placebo

Active not recruitingII

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

Start Date: October 18, 2023
Compounds: Ketamine

Intramuscular Ketamine for Suicidal Ideation

Start Date: February 1, 2022
Compounds: Ketamine, Placebo

Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD

Start Date: June 4, 2021
Compounds: Ketamine

Ketamine and Nitroprusside for Depression

Start Date: February 14, 2017
Compounds: Placebo, Ketamine

Ketamine Plus Lithium in Treatment-Resistant Depression

Start Date: January 7, 2013
Compounds: Ketamine, Placebo

Treatment Study of Bipolar Depression

Start Date: July 1, 2009
Compounds: Ketamine

Collaborated Trials

4

Enrolling by invitationIV

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)

Start Date: October 1, 2023
Compounds: Ketamine, Placebo

Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer

Start Date: December 20, 2016
Compounds: Ketamine, Placebo

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Start Date: December 1, 2014
Compounds: Ketamine, Placebo

Optimization of IV Ketamine for Treatment Resistant Depression

Start Date: January 11, 2008
Compounds: Ketamine, Placebo